Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

Via Peters

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA […]

Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population

Via Peters

Abstract Objective To assess whether eldecalcitol, an active vitamin D analogue2, can reduce the development of type 2 diabetes among adults with impaired glucose tolerance. Design Double blinded, multicentre, randomised, placebo controlled trial. Setting Three hospitals in Japan, between June 2013 and August 2019. Participants People aged 30 years and […]

Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer

Via Peters

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform optimized treatment decision-making, today announced 10,000 patients have been successfully enrolled in the FLEX Registry. Agendia’s unique FLEX Registry […]

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer

Via Peters

FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of topical submicron particle paclitaxel (SOR007) in cutaneous metastases of breast cancer (CMBOC) have been published in Breast Cancer Research and Treatment. The research article entitled Phase 1/2 Study of Topical […]

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial

Via Peters

Background Anticancer treatment regimens typically cause unpleasant side-effects. We aimed to investigate the benefit of switch maintenance endocrine therapy plus bevacizumab after fixed cycles of first-line induction chemotherapy with weekly paclitaxel plus bevacizumab in patients with oestrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer. Methods BOOSTER was a prospective, […]

A Normalized Real-Life Glucose Profile After Diet-Induced Remission of Type 2 Diabetes: A Pilot Trial

Via Peters

In the majority of individuals, type 2 diabetes occurs related to metabolic syndrome, i.e., in the context of overweight/obesity, ectopic fat accumulation, metabolic inflammation, and insulin resistance [1]. However, alternative pathophysiologic processes, unrelated to metabolic syndrome, can also lead to this disease [1-4]. Historically, type 2 diabetes was viewed as […]

A large trial of screening for gestational diabetes mellitus in the United States highlights the need to revisit the Australian diagnostic criteria

Via Peters

Recent trial results validate previous concerns about the IADPSG criteria for gestational diabetes The definition of gestational diabetes mellitus (GDM) varies considerably depending on the region where a woman lives, and considerable controversy remains on the best approach to diagnosis. A 2021 trial showed no benefit for women or infants […]

RxPONDER Trial Another Step in Defining Which Patients With Breast Cancer May Be Spared Adjuvant Cytotoxic Chemotherapy

Via Peters

By Gini F. Fleming, MD, FASCOFebruary 10, 2022 As reported by Kalinsky et al and summarized in this issue of The ASCO Post, an interim analysis of the phase III RxPONDER trial showed that the addition of adjuvant chemotherapy to endocrine therapy improved invasive disease–free survival among premenopausal—but not postmenopausal—women […]